JP6978122B2 - 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 - Google Patents

自閉症および関連障害の治療および予防のための腸管選択的隔離剤 Download PDF

Info

Publication number
JP6978122B2
JP6978122B2 JP2020502532A JP2020502532A JP6978122B2 JP 6978122 B2 JP6978122 B2 JP 6978122B2 JP 2020502532 A JP2020502532 A JP 2020502532A JP 2020502532 A JP2020502532 A JP 2020502532A JP 6978122 B2 JP6978122 B2 JP 6978122B2
Authority
JP
Japan
Prior art keywords
mice
intestinal
metabolites
sequestering
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2020502532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513032A5 (https=
JP2020513032A (ja
Inventor
キャンベル，アンソニー，スチュワート
ドナベディアン，デヴィッド，エイチ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapeutics Inc
Original Assignee
Axial Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Biotherapeutics Inc filed Critical Axial Biotherapeutics Inc
Publication of JP2020513032A publication Critical patent/JP2020513032A/ja
Publication of JP2020513032A5 publication Critical patent/JP2020513032A5/ja
Application granted granted Critical
Publication of JP6978122B2 publication Critical patent/JP6978122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020502532A 2017-03-31 2018-03-31 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 Expired - Fee Related JP6978122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Publications (3)

Publication Number Publication Date
JP2020513032A JP2020513032A (ja) 2020-04-30
JP2020513032A5 JP2020513032A5 (https=) 2021-04-15
JP6978122B2 true JP6978122B2 (ja) 2021-12-08

Family

ID=63677186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502532A Expired - Fee Related JP6978122B2 (ja) 2017-03-31 2018-03-31 自閉症および関連障害の治療および予防のための腸管選択的隔離剤

Country Status (9)

Country Link
US (4) US10617718B2 (https=)
EP (1) EP3600349A4 (https=)
JP (1) JP6978122B2 (https=)
KR (1) KR102328323B1 (https=)
CN (2) CN114569633B (https=)
AU (3) AU2018243836B9 (https=)
BR (1) BR112019020289A2 (https=)
CA (2) CA3095724C (https=)
WO (1) WO2018183986A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6978122B2 (ja) 2017-03-31 2021-12-08 アキシャル セラピューティクス，インク． 自閉症および関連障害の治療および予防のための腸管選択的隔離剤
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
CN114829629A (zh) * 2019-12-19 2022-07-29 希尔氏宠物营养品公司 治疗和降低患上与犬科动物的升高的4-乙基苯基硫酸盐相关的病状的风险的组合物和方法以及鉴定有风险患上此类病状的犬科动物的方法
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
CN101084206A (zh) * 2004-12-13 2007-12-05 艾尼纳制药公司 作为5ht2c受体调节剂以治疗与其相关病症的n－联芳基和n－芳基杂芳基2－经取代哌嗪衍生物
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
CN103491949B (zh) * 2011-03-04 2017-02-08 株式会社吴羽 片剂型的口服给药用组合物及其制造方法
WO2012161921A1 (en) * 2011-05-23 2012-11-29 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
US10060932B2 (en) 2013-07-09 2018-08-28 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
JP2016525138A (ja) * 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20170020999A1 (en) * 2014-04-04 2017-01-26 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract
JP6978122B2 (ja) 2017-03-31 2021-12-08 アキシャル セラピューティクス，インク． 自閉症および関連障害の治療および予防のための腸管選択的隔離剤

Also Published As

Publication number Publication date
AU2018243836B2 (en) 2021-04-22
AU2018243836B9 (en) 2021-05-13
EP3600349A1 (en) 2020-02-05
CN114569633B (zh) 2023-11-17
US20180303876A1 (en) 2018-10-25
CA3095724C (en) 2023-04-18
AU2018243836A1 (en) 2019-11-21
CN110944650A (zh) 2020-03-31
KR20200024133A (ko) 2020-03-06
US11007219B2 (en) 2021-05-18
CA3095724A1 (en) 2018-10-04
US20200368276A1 (en) 2020-11-26
EP3600349A4 (en) 2020-09-30
BR112019020289A2 (pt) 2020-09-01
KR102328323B1 (ko) 2021-11-19
US20230364135A1 (en) 2023-11-16
CN114569633A (zh) 2022-06-03
JP2020513032A (ja) 2020-04-30
AU2021206871A1 (en) 2021-08-12
AU2021206871B2 (en) 2021-10-14
NZ758692A (en) 2022-03-25
CN110944650B (zh) 2022-03-04
AU2022200220A1 (en) 2022-02-10
US10617718B2 (en) 2020-04-14
US20200390809A1 (en) 2020-12-17
CA3191747A1 (en) 2018-10-04
WO2018183986A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
JP6978122B2 (ja) 自閉症および関連障害の治療および予防のための腸管選択的隔離剤
ES2859758T3 (es) Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intestinal
TW201919668A (zh) 包含細菌品系之組成物
WO2017205302A1 (en) Regulate gut microbiota to treat neurodegenerative disorders
US11123379B2 (en) Compositions comprising bacterial strains
EP3979830A1 (en) Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
TW202116333A (zh) 包含細菌品系之組成物
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
JP2006176450A (ja) 小腸でのリンの過剰吸収を抑制可能とする乳酸菌含有組成物
Mishra et al. Gut-Brain Axis: Understanding the Interlink Between Alterations in the Gut Microbiota and Autism Spectrum Disorder
KR20210021085A (ko) 박테리아 균주를 포함하는 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210302

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210302

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211104

R150 Certificate of patent or registration of utility model

Ref document number: 6978122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees